Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25025464 | 1.00 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL25025575 | 1.00 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL26238484 | 1.00 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL25025462 | 1.00 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL26240496 | 1.00 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL25025558 | 0.99 | ADORA1 (0.49) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL4455502 | 0.87 | SLC29A1 (0.55) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL7245383 | 0.87 | SLC29A1 (0.55) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL19509820 | 0.87 | ADORA1 (0.50) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 | |
| SCHEMBL21652362 | 0.87 | ADORA1 (0.50) | ADORA1ADORA3ADORA2AADORA2BSLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230277675-A1 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | NOVO NORDISK A/S (DK) | 2023-09-07 | — | — | US | disclosed |
| WO-2022031433-A9 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | DICERNA PHARMACEUTICALS, INC. (US) | 2023-02-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277675-A1 | SYSTEMIC DELIVERY OF OLIGONUCLEOTIDES | DCLRE1B, RNMT, CD2BP2 | ADORA1 421/4885ADORA3 139/4885ADORA2A 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.